
Sierra Oncology Inc (NASDAQ:SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE:GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion.
GSK believes Sierra Oncology's momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia.